Zachary S. Wallace

Jan 17, 2025 | acrjournals.onlinelibrary.wiley.com | Leonard Calabrese |Michael Putman |Jeffrey A Sparks |Zachary S. Wallace

Corresponding Author Leonard H Calabrese DO Cleveland Clinic, Cleveland Clinic Lerner College of Medicine Corresponding author: Leonard H. Calabrese, D.O., Professor of Medicine, Cleveland Clinic Lerner College of Medicine, RJ Fasenmyer Chair of Clinical Immunology, Vice Chairman, Department of Rheumatic and Immunologic Diseases, 9500 Euclid Avenue, Desk A50, Cleveland, Ohio 44195, Phone: (216) 444-5258, Fax: (216) 445-7569.

Jun 5, 2024 | healio.com | Shenaz Bagha |Zachary S. Wallace

You've successfully added Practice Management in Rheumatology to your alerts. You will receive an email when new content is published. Click Here to Manage Email Alerts We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Key takeaways: Uplizna met all primary and secondary endpoints for treatment of IgG4 related disease.

May 6, 2024 | acrjournals.onlinelibrary.wiley.com | Sebastian E. Sattui |Zachary S. Wallace

Editorial Patient-Reported Outcomes in Antineutrophil Cytoplasmic Antibody–Associated Vasculitis: Are the Answers in Front of Our Noses? Sebastian E. Sattui,  Sebastian E. Sattui University of Pittsburgh, Pennsylvania Contribution: Conceptualization, Writing - original draft, Writing - review & editingSearch for more papers by this authorZachary S. Wallace,  Corresponding Author Zachary S.

Aug 30, 2023 | acrjournals.onlinelibrary.wiley.com | Jinoos Yazdany |Anna Ware |Zachary S. Wallace |Suleman Bhana

Supporting Information Filename Description acr25220-sup-0001-Disclosureform.pdfPDF document, 1.6 MB Disclosure Form acr25220-sup-0002-Tables.docxWord 2007 document , 116.3 KB Supplementary Tables

Aug 29, 2023 | acrjournals.onlinelibrary.wiley.com | Zachary S. Wallace |John Stone |Xiaoqing Fu |Peter A. Merkel

Objective Fixed and tailored rituximab retreatment strategies to maintain remission in antineutrophil cytoplasmic antibody (ANCA)–associated vasculitis (AAV) are associated with tradeoffs. The current study was undertaken to develop a simulation model (AAV-Sim) to project clinical outcomes with these strategies. Methods We developed the AAV-Sim, a microsimulation model of clinical events among individuals with AAV initiating treatment to maintain remission.